These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27094354)

  • 61. A Comparative Investigation of the Ability of Various Aptamer-Functionalized Drug Nanocarriers to Induce Selective Apoptosis in Neoplastic Hepatocytes: In Vitro and In Vivo Outcome.
    Chakraborty S; Dlie ZY; Mukherjee B; Besra SE; Sengupta S; Sen R; Mukherjee A
    AAPS PharmSciTech; 2020 Feb; 21(3):89. PubMed ID: 32026264
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro.
    Zhu L; Shan LJ; Liu YJ; Chen D; Xiao XG; Li Y
    J Dig Dis; 2014 Dec; 15(12):684-93. PubMed ID: 25214410
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
    Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
    Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aptamer-functionalized liposomes for targeted cancer therapy.
    Moosavian SA; Sahebkar A
    Cancer Lett; 2019 Apr; 448():144-154. PubMed ID: 30763718
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells.
    Dapas B; Pozzato G; Zorzet S; Capolla S; Macor P; Scaggiante B; Coan M; Guerra C; Gnan C; Gattei V; Zanconati F; Grassi G
    Int J Pharm; 2020 Jan; 574():118895. PubMed ID: 31862491
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of P22 viral capsid nanocomposites as anti-cancer drug, bortezomib (BTZ), delivery nanoplatforms.
    Min J; Moon H; Yang HJ; Shin HH; Hong SY; Kang S
    Macromol Biosci; 2014 Apr; 14(4):557-64. PubMed ID: 24847525
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.
    Yin X; Rong J; Shao M; Zhang S; Yin L; He Z; Wang X
    J Nanobiotechnology; 2024 May; 22(1):243. PubMed ID: 38735927
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Selection and Characterization of a Novel DNA Aptamer, Apt-07S Specific to Hepatocellular Carcinoma Cells.
    Yu XX; Ge KL; Liu N; Zhang JY; Xue ML; Ge YL
    Drug Des Devel Ther; 2020; 14():1535-1545. PubMed ID: 32368012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antitumor Effects and Delivery Profiles of Menahydroquinone-4 Prodrugs with Ionic or Nonionic Promoiety to Hepatocellular Carcinoma Cells.
    Setoguchi S; Watase D; Matsunaga K; Yamakawa H; Goto S; Terada K; Ohe K; Enjoji M; Karube Y; Takata J
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30013007
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer.
    Meng L; Yang L; Zhao X; Zhang L; Zhu H; Liu C; Tan W
    PLoS One; 2012; 7(4):e33434. PubMed ID: 22558072
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach.
    Dhara M; Al Hoque A; Sen R; Dutta D; Mukherjee B; Paul B; Laha S
    J Nanobiotechnology; 2023 Jan; 21(1):28. PubMed ID: 36694259
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetic and Pharmacodynamic Evaluation of Resveratrol Loaded Cationic Liposomes for Targeting Hepatocellular Carcinoma.
    Jagwani S; Jalalpure S; Dhamecha D; Jadhav K; Bohara R
    ACS Biomater Sci Eng; 2020 Sep; 6(9):4969-4984. PubMed ID: 33455290
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1-actin Complex as a New Potential Target for Therapy.
    Bosutti A; Dapas B; Grassi G; Bussani R; Zanconati F; Giudici F; Bottin C; Pavan N; Trombetta C; Scaggiante B
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456960
    [TBL] [Abstract][Full Text] [Related]  

  • 74. TGF-beta inihibitor-loaded polyelectrolyte multilayers capsules for sustained targeting of hepatocarcinoma cells.
    Vergaro V; Baldassarre F; De Santis F; Ciccarella G; Giannelli G; Leporatti S
    Curr Pharm Des; 2012; 18(27):4155-64. PubMed ID: 22630086
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma.
    Zhang X; Lin C; Lu A; Lin G; Chen H; Liu Q; Yang Z; Zhang H
    Drug Deliv; 2017 Nov; 24(1):986-998. PubMed ID: 28644728
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
    Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
    Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In Vivo Use of a Multi-DNA Aptamer-Based Payload/Targeting System To Study Dopamine Dysregulation in the Central Nervous System.
    McConnell EM; Ventura K; Dwyer Z; Hunt V; Koudrina A; Holahan MR; DeRosa MC
    ACS Chem Neurosci; 2019 Jan; 10(1):371-383. PubMed ID: 30160936
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.
    Van Goietsenoven G; Hutton J; Becker JP; Lallemand B; Robert F; Lefranc F; Pirker C; Vandenbussche G; Van Antwerpen P; Evidente A; Berger W; Prévost M; Pelletier J; Kiss R; Kinzy TG; Kornienko A; Mathieu V
    FASEB J; 2010 Nov; 24(11):4575-84. PubMed ID: 20643906
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Study on the Method of Isolating the Aptamer from the Surface of HepG2 Cells.
    Guo Z; Wang C; Li S; Chen Z; Deng Y; He N
    J Nanosci Nanotechnol; 2020 Jun; 20(6):3373-3377. PubMed ID: 31748029
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development and in functional study of a bi-specific sustained release drug-loaded nano-liposomes for hepatocellular carcinoma.
    Zhang Y; Wu X; Zhu H; Cong Y
    J Biomater Appl; 2023 Jul; 38(1):97-108. PubMed ID: 37243614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.